<DOC>
	<DOCNO>NCT02343952</DOCNO>
	<brief_summary>This open label , multi-institutional , single arm phase II trial consolidation therapy pembrolizumab , follow initial treatment concurrent chemoradiation patient inoperable unresectable stage IIIA IIIB NSCLC . No randomization blind involve .</brief_summary>
	<brief_title>Consolidation Pembrolizumab Following Chemoradiation Patients With Inoperable/Unresectable Stage III NSCLC</brief_title>
	<detailed_description>OUTLINE : This multi-center study . Eligible patient must complete concurrent chemoradiation standard chemotherapy regimen ( either cisplatin/etoposide carboplatin/paclitaxel ) dose radiation range 59.4-66.6Gy , restaging complete 28 day 56 day post-chemoradiation . Patients progressive disease eligible investigational treatment . Patients stable disease/response eligible register investigational treatment consolidation therapy begin minimum 28 day maximum 56 day completion chemoradiotherapy . INVESTIGATIONAL TREATMENT : Pembrolizumab , 200 mg IV every 3 week ( progressive disease ( PD ) , unacceptable toxicity , 12 month ( 52 week ) therapy pembrolizumab . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Hematopoietic : - Absolute neutrophil count ( ANC ) ≥1,500/mcL - Platelets ≥100,000/mcL - Hemoglobin ≥9 g/dL ≥5.6 mmol/L Renal : - Serum creatinine OR measure calculated creatinine clearance ≤1.5 X institutional upper limit normal ( ULN ) OR ≥60 mL/min subject creatinine level &gt; 1.5 X institutional ULN ( glomerular filtration rate ( GFR ) also use place creatinine CrCl ) Hepatic : - Serum total bilirubin ≤ 1.5 X institutional ULN OR direct bilirubin ≤ ULN subject total bilirubin level &gt; 1.5 institutional ULN - Aspartate transaminase ( AST ) , serum glutamic oxaloacetic transaminase ( SGOT ) , alanine transaminase ( ALT ) , serum glutamic pyruvic transaminase ( SGPT ) ≤ 2.5 X institutional ULN Coagulation : - International Normalized Ratio ( INR ) Prothrombin Time ( PT ) ≤1.5 X institutional ULN unless subject receive anticoagulant therapy long PT/INR/PTT within therapeutic range intend use anticoagulant .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histological cytological evidence NSCLC Must unresectable inoperable stage IIIA IIIB disease . Patients consider unresectable inoperable base judgment treat physician Must complete concurrent chemoradiation standard chemotherapy regimen ( either cisplatin/etoposide carboplatin/paclitaxel ) dose radiation range 59.466.6Gy Must stable disease disease response evidence CT evaluation minimum 28 day maximum 56 day follow completion chemoradiation Women childbearing potential must willing use two method contraception abstain heterosexual activity point registration 120 day last dose study drug Male subject childbearing potential must agree use adequate method contraception start first dose study drug 120 day last dose study drug Age ≥ 18 year time consent Written inform consent HIPAA authorization release personal health information Pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment Active central nervous system ( CNS ) metastases . Subjects must undergo head compute tomography ( CT ) scan brain MRI within 28 day prior registration protocol therapy exclude brain metastasis symptomatic without prior brain imaging Treatment investigational agent within 28 day prior registration protocol therapy Prior chemotherapy , adjuvant therapy , radiotherapy lung cancer , standard concurrent chemoradiation describe Prior therapy PD1 , PDL1 , CTLA4 inhibitor lung cancerspecific vaccine therapy Presence metastatic disease ( stage IV NSCLC ) allow . Subjects must evaluate PET scan within 28 day prior registration protocol therapy exclude metastatic disease No active second cancer Evidence active autoimmune disease require systemic treatment within past 90 day document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy would exception rule . Subjects require intermittent use bronchodilator local steroid injection would exclude study . Subjects hypothyroidism stable hormone replacement Sjogren 's syndrome exclude study Interstitial lung disease history pneumonitis require treatment corticosteroid Diagnosis immunodeficiency receive chronic systemic corticosteroid therapy immunosuppressive therapy ( excludes inhale corticosteroid ) within 7 day first dose study drug History psychiatric illness social situation would limit compliance study requirement Clinically active infection judge treat investigator ( ≥ Grade 2 CTCAE v4 ) include know human immunodeficiency virus ( HIV ) infection chronic hepatitis B C Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pembrolizumab</keyword>
	<keyword>MK-3475</keyword>
</DOC>